We are live on ! Find out more
AKRO

Akero Therapeutics
AKRO

Delisted

AKRO was delisted on the 8th of December, 2025.

Back to rankings

102 hedge funds and large institutions have $888M invested in Akero Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 40 increasing their positions, 23 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

383% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 6

74% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 23

63% more capital invested

Capital invested by funds: $545M → $888M (+$343M)

29% more funds holding

Funds holding: 79 → 102 (+23)

7.3% more ownership

Funds ownership: 76.24% → 83.54% (+7.3%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

79% less call options, than puts

Call options by funds: $289K | Put options by funds: $1.4M

Holders
102
Holders Change
+23
Holders Change %
+29.11%
% of All Funds
2.06%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
29
Increased
40
Reduced
23
Closed
6
Calls
$289K
Puts
$1.4M
Net Calls
-$1.11M
Net Calls Change
-$446K

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$67.9M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$62.4M
3
Alkeon Capital Management
Alkeon Capital Management
New York
+$44.8M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$27.9M
5
HA
HHLR Advisors
Cayman Islands
+$21M

Top Sellers

Rank Fund Capital Flow
1
VVM
Versant Venture Management
California
-$46.8M
2
VP
venBio Partners
California
-$24.7M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$10.6M
4
Morgan Stanley
Morgan Stanley
New York
-$4.49M
5
PHP
Parkman Healthcare Partners
Connecticut
-$2.37M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$2.18M +$1.06M +30,240 +74%
N
27
Nuveen
North Carolina
$2.12M +$843K +24,133 +54%
Two Sigma Investments
28
Two Sigma Investments
New York
$2.05M +$1.66M +47,471 +250%
EI
29
EAM Investors
California
$1.97M +$2.23M +63,928 New
Goldman Sachs
30
Goldman Sachs
New York
$1.9M -$315K -9,013 -13%
JP Morgan Chase
31
JP Morgan Chase
New York
$1.83M -$183K -5,237 -8%
Jacobs Levy Equity Management
32
Jacobs Levy Equity Management
New Jersey
$1.74M -$278K -7,943 -12%
EGI
33
EAM Global Investors
California
$1.53M +$1.74M +49,718 New
AA
34
ALPS Advisors
Colorado
$1.36M +$179K +5,136 +13%
CLCM
35
Crawford Lake Capital Management
New Jersey
$1.35M +$1.53M +43,826 New
Citadel Advisors
36
Citadel Advisors
Florida
$1.25M -$591K -16,924 -29%
Federated Hermes
37
Federated Hermes
Pennsylvania
$1.19M +$1.35M +38,538 +48,782%
Renaissance Technologies
38
Renaissance Technologies
New York
$1.11M +$60K +1,716 +5%
Swiss National Bank
39
Swiss National Bank
Switzerland
$1.06M +$426K +12,200 +54%
Bank of America
40
Bank of America
North Carolina
$991K +$815K +23,321 +263%
California Public Employees Retirement System
41
California Public Employees Retirement System
California
$969K +$236K +6,760 +27%
PPA
42
Parametric Portfolio Associates
Washington
$925K +$1.05M +30,045 New
CPIG
43
Chicago Partners Investment Group
Illinois
$833K – – –
MAM
44
Martingale Asset Management
Massachusetts
$804K +$912K +26,105 New
Victory Capital Management
45
Victory Capital Management
Texas
$771K -$303K -8,666 -26%
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$711K -$178K -5,093 -18%
PA
47
Perceptive Advisors
New York
$675K +$767K +21,938 New
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$631K +$127K +3,623 +21%
Ensign Peak Advisors
49
Ensign Peak Advisors
Utah
$595K -$275K -7,881 -29%
AllianceBernstein
50
AllianceBernstein
Tennessee
$576K -$119K -3,400 -15%
1
2
3 4 5

AKRO Hedge Fund Activity: Q3 2020 in Review

102 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q3 2020, worth a combined $888M — up 63% from $545M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new AKRO positions and 6 closed out — a net gain of 23 holders — while 40 added to existing stakes and 23 trimmed.

The largest buyer was Redmile Group, adding an estimated $67.9M. The largest seller was Versant Venture Management, cutting an estimated $46.8M.

  • 102 institutional investors held Akero Therapeutics (AKRO) as of Q3 2020, up from 79 in Q2 2020.
  • Funds reported $888M of Akero Therapeutics stock for Q3 2020, up 63% quarter-over-quarter.
  • 29 funds opened new Akero Therapeutics positions in Q3 2020 and 6 closed out, a net change of +23 holders.
  • The largest Akero Therapeutics buyer in Q3 2020 was Redmile Group, an estimated $67.9M added.
  • The largest Akero Therapeutics seller in Q3 2020 was Versant Venture Management, an estimated $46.8M sold.

Based on aggregated 13F filings for Q3 2020.